

TEZSPIRE (TEZEPELUMAB-EKKO) INJECTION ORDERS

FAX: 470.922.3656 | PHONE: 470.377.6400

PATIENT INFORMATION: Fax completed	d form, insurance information, and clinical documentation to 470.922.3656			
Patient Name:	DOB: Phone:			
Patient Status: New to Therapy Continuing The state of	nerapy Next Treatment Date:			
MEDICAL INFORMATION				
Diagnosis: Severe persistent asthma, uncompli	cated (ICD-10 code: J45.50)			
Severe persistent asthma with acute				
□ Other:	(ICD-10 code:)			
Patient Weight: lbs. (required) Allergies:				
THERAPY ORDER				
Tezspire: 210mg subcutaneously every 4 weeks x 1 year				
Lab Orders:	Lab Frequency:			
Required labs to be drawn by:	enter 🛛 Referring Provider			
Other orders:				

PROVIDER INFO	RMATION				
	services, you are authorizing <i>Biocare Infusion</i> , ascription insurance companies, and to select			esignated	
Provider Name:		Signature:		Date:	
Provider NPI:	Phone:	Fax:	Contact Person:		
□Opt out of Biocare Infusion selecting site of care (if checked, please list site of care):					
PREFERRED LOCATION					
City:	State:	_ View our	locations here:		
	intended to be delivered only to the named			•	

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



COMPREHENSIVE SUPPORT FOR TEZSPIRE THERAPY

PATIENT INFORMATION:	
Patient Name:	DOB:
REQUIRED DOCUMENTATION FOR REFERRAL	PROCESSING & INSURANCE APPROVAL
Include signed and completed order (MD/prescrit	per to complete page 1)
Include patient demographic information and insu	arance information
Include patient's medication list	
Supporting clinical notes to include any past tried benefits, or contraindications to conventional the	
Please indicate any tried and failed therapies Corticosteroids	s (if applicable):
Long acting beta 2 agonist	
Long acting muscarinic antagonist	
Leukotriene receptor antagonist	
Please indicate any that apply to the patient	
☐ Poor symptom control (ACQ score ≥ 1.5 c ☐ Two or more burst of systemic corticosterc previous 12 months	
\Box Asthma-related emergency treatment	
\Box Airflow limitation (FEV1 < 80% predicted)	
\Box Dependent on oral corticosteroids for asth	ma maintenance
□ Include labs and/or test results to support diagn	osis
Pulmonary Function Tests (attach)	
Other medical necessity:	

Biocare Infusion will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (470) 922-3656 or call (470) 377-6400 for assistance

BIOCAREINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.